Macular Telangiectasia (MacTel) - Pipeline Insight, 2023

Macular Telangiectasia (MacTel) - Pipeline Insight, 2023

DelveInsight’s, “Macular Telangiectasia (MacTel) - Pipeline Insight, 2023” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Macular Telangiectasia (MacTel) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Macular Telangiectasia (MacTel): Understanding

Macular Telangiectasia (MacTel): Overview

Macular Telangiectasia (MacTel) (MacTel) is a disease affecting the macula, causing loss of central vision. MacTel develops when there are problems with the tiny blood vessels around the fovea. There are two types of MacTel, Type 1 MacTel and Type 2 MacTel. In MacTel type 1, the blood vessels become dilated and leads to tiny aneurysms, causing swelling and damaging macular cells. The disease almost always occurs in one eye, which differentiates it from Type 2. Type 2 MacTel is the most common form. In MacTel type 2 the capillaries around the fovea widen (become dilated) and leak. This causes fluid build-up and swelling, impairing reflection of light and causing progressive vision loss. As damage continues, new blood vessels may form, which can break and leak. This can lead to the development of scar tissue, further impairing central vision. MacTel type 2 affects both eyes and occurs most often in middle-aged adult.

In the early stages, people with MacTel will have no symptoms. As the disease progresses, blurring, distorted vision, and loss of central vision are common. Loss of central vision progresses over a period of 10 – 20 years. MacTel does not affect side vision and does not usually cause total blindness.

A diagnosis of Macular Telangiectasia (MacTel) is made based upon a thorough assessment of vision, and a variety of specialized tests. A small, fine crystals in the center of your macula is a sign of MacTel. Other findings are discoloration of the macula, abnormal blood vessels in the center of the macula, lipid (fat) deposits, and pigment clumps. Testing with an Amsler grid is done to detect any wavy or dark areas in central vision. Optical coherence tomography (OCT) and fluorescein angiography (FA) are done to check the conditions of retina.

Treatment options for Macular Telangiectasia (MacTel) are limited. The variable course of progression of the disease makes it difficult to assess the efficacy of treatments. Treatment for MacTel in the absence of retinal neovascularization is supportive, as there is currently no proven therapy has been shown to prevent progression. Macular grid laser photocoagulation, photodynamic therapy, and intravitreal injections of vascular endothelial growth factor (VEGF) antagonists have been tried. Currently there are new therapies under development for the treatment of Macular Telangiectasia (MacTel).

""Macular Telangiectasia (MacTel) - Pipeline Insight, 2023"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Macular Telangiectasia (MacTel) pipeline landscape is provided which includes the disease overview and Macular Telangiectasia (MacTel) treatment guidelines. The assessment part of the report embraces, in depth Macular Telangiectasia (MacTel) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Macular Telangiectasia (MacTel) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Macular Telangiectasia (MacTel) R&D. The therapies under development are focused on novel approaches to treat/improve Macular Telangiectasia (MacTel).

Macular Telangiectasia (MacTel) Emerging Drugs Chapters

This segment of the Macular Telangiectasia (MacTel) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Macular Telangiectasia (MacTel) Emerging Drugs

NT-501: Neurotech Pharmaceuticals

NT-501 (Renexus) is an encapsulated cell therapy for treatment of Macular Telangiectasia (MacTel). NT-501 is currently in Phase 3, randomized, multi-center study to evaluate the efficacy and safety of the Renexus implants in participants with Macular Telangiectasia (MacTel) type 2. NT-501 is a novel cell-based drug-delivery system in which human-derived cells encapsulated in a semipermeable hollow fiber membrane device release ciliary neurotrophic factor (CNTF). NT 501 was granted orphan drug status for retinal (macular) telangiectasia type 2 by the FDA in July 2012. In February 2019 FDA granted Fast Track designation to NT-501 or Renexus, for the treatment of Macular Telangiectasia (MacTel) type 2 (MacTel).

THR 317: OXURION

THR-317 is a Placenta growth factor (PlGF) inhibitor. THR-317 is being evaluated in a Phase II study for the treatment of Idiopathic Macular Telangiectasia (MacTel) Type 1 (MacTel 1).

Further product details are provided in the report……..

Macular Telangiectasia (MacTel) : Therapeutic Assessment

This segment of the report provides insights about the different Macular Telangiectasia (MacTel) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Macular Telangiectasia (MacTel)

There are approx. 4+ key companies which are developing the therapies for Macular Telangiectasia (MacTel). The companies which have their Macular Telangiectasia (MacTel) drug candidates in the most advanced stage, i.e. phase III include, Neurotech Pharmaceuticals.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Macular Telangiectasia (MacTel) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Subcutaneous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibody

Small molecule

Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Macular Telangiectasia (MacTel): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Macular Telangiectasia (MacTel) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Macular Telangiectasia (MacTel) drugs.

Macular Telangiectasia (MacTel) Report Insights

Macular Telangiectasia (MacTel) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Macular Telangiectasia (MacTel) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Macular Telangiectasia (MacTel) drugs?

How many Macular Telangiectasia (MacTel) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Macular Telangiectasia (MacTel)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Macular Telangiectasia (MacTel) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Macular Telangiectasia (MacTel) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

OXURION

Neurotech Pharmaceuticals

Key Products

THR 317

NT-501